The investors in CytomX Therapeutics, Inc.‘s (NASDAQ:CTMX) will be rubbing their hands together with glee today, after the share price leapt 27% to US$14.24 in the week following its first-quarter results. Revenues beat expectations by 136%, and sales of US$50m were sufficient to generate a statutory profit of US$0.26 – a pleasant surprise given that the analysts were forecasting a loss! Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there’s been a strong change in the company’s prospects, or if it’s business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
About The Author
January 20, 2019